0155.KLSE Malaysian Genomics Resource
- Market cap
- MYR 48.3M
- P/E
- -
- P/B
- 2.42x
- ROE
- -15.1%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 0155.KLSE undervalued?
Graham numberThe Graham number of Malaysian Genomics Resource cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Malaysian Genomics Resource fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-15.1%), below 10%.
ROA 1/1
Return on assets (-12.7%) is above the industry median (-19.8%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (43.2%) is above the industry median (3.8%).
Revenue Growth 0/2
Revenue shrank 1.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Loss-making but free cash flow is positive.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (2.4x) is below the industry median (3.1x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
About Malaysian Genomics Resource
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia. The company offers genetic screening services that includes Dtect and Origene genetic testing solutions which provides individuals with insights into genetic predispositions related to health risks, wellness, and lifestyle traits. It also provides immunotherapy and cell therapy which offers mesenchymal stem cells d…
Full company profileMalaysian Genomics Resource financial statements
Malaysian Genomics Resource annual financial statements (MYR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 9.87M | 26.2M | 283K | 951K | 1.78M | 28.4M | 8.36M | 12.9M | 5.52M | 8.02M |
| Gross Profit | 6.92M | 9.14M | -118K | 623K | 1.21M | 13.9M | 5.10M | 7.50M | 3.43M | 5.14M |
| Operating Income | 578K | -3.71M | -4.74M | -6.05M | -4.20M | 6.28M | -13.6M | -22.4M | -4.40M | -729K |
| EBITDA | 1.48M | -2.12M | -1.40M | -4.37M | -3.62M | 7.42M | - | - | -2.82M | -925K |
| Net Income | 589K | -4.53M | -3.84M | 17.1M | -4.29M | 7.21M | -14.2M | -21.5M | -4.19M | -2.38M |
| EPS | 0.01 | -0.04 | -0.04 | 0.17 | -0.04 | 0.06 | -0.11 | -0.16 | -0.03 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 37.8M | 40.8M | 37.0M | 11.1M | 22.8M | 41.9M | 30.9M | 25.7M | 22.4M | 18.7M |
| Total Liabilities | 13.5M | 21.1M | 21.1M | 828K | 4.85M | 4.84M | 4.08M | 3.36M | 4.20M | 3.92M |
| Shareholders' Equity | 24.3M | 19.8M | 15.9M | 10.3M | 17.9M | 37.0M | 26.8M | 22.3M | 18.2M | 15.8M |
| Cash & Short-term Investments | 1.88M | 7.38M | 4.33M | 6.08M | 11.3M | 20.5M | 1.69M | 1.42M | 271K | 1.02M |
| Total Debt | 4.50M | 14.7M | 14.2M | - | 1.30M | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.67M | -6.34M | -688K | 11.7M | -2.64M | 56.9K | -22.1M | -25.0M | -745K | 1.10M |
| Capital Expenditure | 143K | 938K | 2.21M | 351K | 3.96M | 1.33M | 442K | 597K | 208K | 71.6K |
| Free Cash Flow | 3.53M | -7.28M | -2.90M | 9.47M | -6.60M | -1.27M | -21.2M | - | -953K | 1.03M |
| Ratios | ||||||||||
| ROE | 2.4% | -22.9% | -24.1% | 166.7% | -23.9% | 19.5% | -53.2% | -96.3% | -23.1% | -15.1% |
| ROA | 1.6% | -11.1% | -10.4% | 154.3% | -18.8% | 17.2% | -46.1% | -83.7% | -18.7% | -12.7% |
| Net Profit Margin | 6.0% | -17.3% | -1,356.5% | 1,797.5% | -240.7% | 25.4% | -170.3% | -167.3% | -75.9% | -29.7% |
| Debt to Equity | 0.19x | 0.74x | 0.89x | - | 0.07x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Malaysian Genomics Resource dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jan 9, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | MYR 22.8M | 0.22 | 133.2% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Malaysian Genomics Resource
- Insiders 58.64%
- Institutions 14.84%
- Public & others 26.52%
- Shares outstanding 151M
- Free float 33.7M
Malaysian Genomics Resource company profile
- Company name
- Malaysian Genomics Resource
- Ticker
- 0155.KLSE
- ISIN
- MYQ0155OO000
- Exchange
- Kuala Lumpur Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- June
- Address
- Jalan Teknologi 3/6, Petaling Jaya, Malaysia, 47810
- Phone
- 60 3 7890 0015
- Website
- mgrc.com.my
About Malaysian Genomics Resource
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia. The company offers genetic screening services that includes Dtect and Origene genetic testing solutions which provides individuals with insights into genetic predispositions related to health risks, wellness, and lifestyle traits. It also provides immunotherapy and cell therapy which offers mesenchymal stem cells derived from ethically sourced human umbilical cords, as well as natural killer cell therapies designed to strengthen the body's immune response that are relevant in the treatment of cancers, autoimmune diseases, and other complex conditions. In addition, the company offers genome sequencing and bioinformatics services; personalized supplements; cellular therapy for regenerative health; and cell-free therapy for regeneration and repair. Further, it is involved in dealing in capital markets and derivative instruments; acting as general merchants; research, development, and commercialization of biopharmaceutical products and services; business relating to life sciences/cell lab and by products; and distribution of healthcare products, beauty products, and precision medicine. Additionally, the company provides system developments and information technology comprising software and hardware, as well as other human health services and general medical services. Malaysian Genomics Resource Centre Berhad was incorporated in 2004 and is headquartered in Petaling Jaya, Malaysia.
Malaysian Genomics Resource management
2- Mr. Yien Hung LeongExecutive Chairman & MD · born 1984
- Mr. Tong Lang TanCompany Secretary · born 1977